Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world characteristics and treatment persistence in patients initiating CLES: Results from a cohort of 1290 patients in USA
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
131
Evaluate real-world characteristics and treatment persistence of carbidopa/levodopa enteral suspension (CLES) in patients with Advanced Parkinson’s Disease (APD).

The continuous delivery of levodopa via CLES has shown significant improvements in managing PD-related symptoms among APD patients. Despite growing experience with CLES, evidence on real-world long-term treatment persistence is scarce.

Retrospective cohort study of APD patients initiating CLES in the United States was conducted. CLES patients were identified through September 2020 based on data from a specialty pharmacy hub. CLES initiation date was based on pharmacy shipment data and defined as index date. CLES naïve patients with 2 or more shipments and minimum of 12 months of observable follow-up were included. Demographic and clinical characteristics were captured at index date. Patients were followed from index date until CLES discontinuation or end of data follow-up. Survival analyses using Kaplan-Meier curves were conducted to evaluate treatment persistence up to 5 years after index date, with death treated as a censoring event. 
In the study sample of CLES patients (n=1,290), 27.1% were younger than 65 years, and 51.9% on Medicare. PD duration at treatment initiation was 11.6±5.9 years. Starting CLES Levodopa daily dose was 1238.5±479.5 mg. Persistence rates on CLES therapy at 1, 2, 3, 4, and 5 years were 81.2%, 70.4%, 60.6%, 54.3%, and 44.9% respectively. Among overall sample, patients remained on CLES therapy for a median (IQR) of 22.5 (12.9-33) months. Over the course of 2545 person years on CLES, 192 patients were censored due to death. Among discontinued patients (not due to death, n=443), median (IQR) time on CLES therapy was 11.3 (4.7-21.1) months.
Patients demonstrated long-term persistence on CLES and nearly half remained on therapy at 5 years. Future studies should explore sociodemographic and clinical predictors of CLES persistence.
Authors/Disclosures
Fernando L. Pagan, MD, FÂ鶹´«Ã½Ó³»­ (Georgetown University Hospital Dept of Neurology)
PRESENTER 		Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Adamas. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa Kirin. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sunovion. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for US World Meds. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Adamas. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amneal. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Parkinsonism and related Disorders. Dr. Pagan has stock in Keiferx. The institution of Dr. Pagan has received research support from US World Meds. The institution of Dr. Pagan has received research support from Novartis.
Ramon L. Rodriguez Cruz, MD, FÂ鶹´«Ã½Ó³»­ (Neurology One) The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus . The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbott. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Kyoway Kirin. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. The institution of Dr. Rodriguez Cruz has received research support from Cerevance. The institution of Dr. Rodriguez Cruz has received research support from Neuraly. The institution of Dr. Rodriguez Cruz has received research support from Amneal. The institution of Dr. Rodriguez Cruz has received research support from Teva. The institution of Dr. Rodriguez Cruz has received research support from Neurocrine. Dr. Rodriguez Cruz has received publishing royalties from a publication relating to health care.
Michael Soileau, MD, FÂ鶹´«Ã½Ó³»­ (Texas Movement Disorder Specialists, PLLC) The institution of Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. The institution of Dr. Soileau has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. The institution of Dr. Soileau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Soileau has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie. Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. The institution of Dr. Soileau has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merz. The institution of Dr. Soileau has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Soileau has received research support from Abbvie. The institution of Dr. Soileau has received research support from Cerevel. The institution of Dr. Soileau has received research support from Praxis. The institution of Dr. Soileau has received research support from CND Life Sciences. The institution of Dr. Soileau has received research support from Teva. The institution of Dr. Soileau has received research support from Abbott. The institution of Dr. Soileau has received research support from Jazz Pharmaceuticals. The institution of Dr. Soileau has received research support from Scion. Dr. Soileau has received publishing royalties from a publication relating to health care. Dr. Soileau has a non-compensated relationship as a Past President with Texas Neurological Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Ali Alobaidi, PharmD (AbbVie Inc) Dr. Alobaidi has received personal compensation for serving as an employee of AbbVie Inc. Dr. Alobaidi has received stock or an ownership interest from AbbVie Inc.
Prasanna L. Kandukuri Mrs. Kandukuri has nothing to disclose.
No disclosure on file
Yash Jalundhwala, PhD (AbbVie Inc) Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . An immediate family member of Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . Dr. Jalundhwala has received stock or an ownership interest from AbbVie.
Omar Ladhani Omar Ladhani has received personal compensation for serving as an employee of AbbVie. Omar Ladhani has received stock or an ownership interest from AbbVie.
Mustafa S. Siddiqui, MD, FÂ鶹´«Ã½Ó³»­ Dr. Siddiqui has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific Neuromodulation. Dr. Siddiqui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Siddiqui has received research support from Boston Scientific Neuromodulation. The institution of Dr. Siddiqui has received research support from Abbvie. The institution of Dr. Siddiqui has received research support from National Institute of Health .